Cargando…
BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer
Background. Molecular diagnostics has offered new techniques for searching for mutations in thyroid indeterminate lesions. The study's aim was to evaluate the BRAF mutations' incidence in an Italian regional population. Subjects and Methods. 70 Caucasian patients born in Liguria with indet...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674605/ https://www.ncbi.nlm.nih.gov/pubmed/26693224 http://dx.doi.org/10.1155/2015/138734 |
_version_ | 1782404923083718656 |
---|---|
author | Monti, Eleonora Bovero, Michela Mortara, Lorenzo Pera, Giorgia Zupo, Simonetta Gugiatti, Elena Dono, Mariella Massa, Barbara Ansaldo, Gian Luca Massimo, Giusti |
author_facet | Monti, Eleonora Bovero, Michela Mortara, Lorenzo Pera, Giorgia Zupo, Simonetta Gugiatti, Elena Dono, Mariella Massa, Barbara Ansaldo, Gian Luca Massimo, Giusti |
author_sort | Monti, Eleonora |
collection | PubMed |
description | Background. Molecular diagnostics has offered new techniques for searching for mutations in thyroid indeterminate lesions. The study's aim was to evaluate the BRAF mutations' incidence in an Italian regional population. Subjects and Methods. 70 Caucasian patients born in Liguria with indeterminate or suspicious cytological diagnoses. Results. A BRAF gene mutation was successfully analyzed in 56/70 patients. The mutation was BRAF V600E in 12/56 cases (21%) and BRAF K601E in 2/56 (4%). Of the BRAF mutated samples on cytological diagnosis (14/56 cases), 2/14 cases (14%) were benign on final histology and 12/14 (86%) were malignant. All BRAF-mutated cases on cytology that were found to be benign on histological examination carried the K601E mutation. Of the nonmutated BRAF cases (42/56, 75%) which were later found to be malignant on definitive histology, 5 cases were follicular carcinomas (36%), 3 cases were incidentally found to be papillary microcarcinomas (22%), 2 were cases papillary carcinomas (14%), 1 was case follicular variant of papillary carcinoma (7%), 1 was case medullary carcinoma (7%), 1 case was Hurtle cell tumor (7%), and 1 case was combined cell carcinoma and papillary oncocytic carcinoma (7%). Conclusions. The presence of the BRAF V600E mutation may suggest a more aggressive surgical approach. BRAF K601E mutation did not correlate with malignancy indexes. |
format | Online Article Text |
id | pubmed-4674605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-46746052015-12-21 BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer Monti, Eleonora Bovero, Michela Mortara, Lorenzo Pera, Giorgia Zupo, Simonetta Gugiatti, Elena Dono, Mariella Massa, Barbara Ansaldo, Gian Luca Massimo, Giusti Int J Endocrinol Research Article Background. Molecular diagnostics has offered new techniques for searching for mutations in thyroid indeterminate lesions. The study's aim was to evaluate the BRAF mutations' incidence in an Italian regional population. Subjects and Methods. 70 Caucasian patients born in Liguria with indeterminate or suspicious cytological diagnoses. Results. A BRAF gene mutation was successfully analyzed in 56/70 patients. The mutation was BRAF V600E in 12/56 cases (21%) and BRAF K601E in 2/56 (4%). Of the BRAF mutated samples on cytological diagnosis (14/56 cases), 2/14 cases (14%) were benign on final histology and 12/14 (86%) were malignant. All BRAF-mutated cases on cytology that were found to be benign on histological examination carried the K601E mutation. Of the nonmutated BRAF cases (42/56, 75%) which were later found to be malignant on definitive histology, 5 cases were follicular carcinomas (36%), 3 cases were incidentally found to be papillary microcarcinomas (22%), 2 were cases papillary carcinomas (14%), 1 was case follicular variant of papillary carcinoma (7%), 1 was case medullary carcinoma (7%), 1 case was Hurtle cell tumor (7%), and 1 case was combined cell carcinoma and papillary oncocytic carcinoma (7%). Conclusions. The presence of the BRAF V600E mutation may suggest a more aggressive surgical approach. BRAF K601E mutation did not correlate with malignancy indexes. Hindawi Publishing Corporation 2015 2015-11-26 /pmc/articles/PMC4674605/ /pubmed/26693224 http://dx.doi.org/10.1155/2015/138734 Text en Copyright © 2015 Eleonora Monti et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Monti, Eleonora Bovero, Michela Mortara, Lorenzo Pera, Giorgia Zupo, Simonetta Gugiatti, Elena Dono, Mariella Massa, Barbara Ansaldo, Gian Luca Massimo, Giusti BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer |
title | BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer |
title_full | BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer |
title_fullStr | BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer |
title_full_unstemmed | BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer |
title_short | BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer |
title_sort | braf mutations in an italian regional population: implications for the therapy of thyroid cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674605/ https://www.ncbi.nlm.nih.gov/pubmed/26693224 http://dx.doi.org/10.1155/2015/138734 |
work_keys_str_mv | AT montieleonora brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer AT boveromichela brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer AT mortaralorenzo brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer AT peragiorgia brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer AT zuposimonetta brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer AT gugiattielena brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer AT donomariella brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer AT massabarbara brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer AT ansaldogianluca brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer AT massimogiusti brafmutationsinanitalianregionalpopulationimplicationsforthetherapyofthyroidcancer |